Antithrombotic effects of targeting αIIbβ3 signaling in platelets

Blood

Volumn 113, Issue 15, 2009, Pages 3585-3592

  Ablooglu, Ararat J ^a   Kang, Jian ^a   Petrich, Brian G ^a   Ginsberg, Mark H ^a   Shattil, Sanford J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ARGININE; CYSTEINE; FERRIC CHLORIDE; FIBRINOGEN; GLYCINE; INTEGRIN; INTEGRIN ALPHAIIBBETA3; LYSINE; PROTEIN TYROSINE KINASE; PROTEINASE ACTIVATED RECEPTOR; THREONINE; UNCLASSIFIED DRUG;

ANEMIA; ANIMAL CELL; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BLEEDING TIME; BLOOD VESSEL INJURY; CARBOXY TERMINAL SEQUENCE; CAROTID ARTERY THROMBOSIS; COMPARATIVE STUDY; CONTROLLED STUDY; GENE DELETION; HETEROZYGOTE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OCCULT BLOOD; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; THROMBOCYTE; WILD TYPE;

EID: 65149095905     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-09-180687     Document Type: Article

References (51)

1. Ruoslahti E, Pierschbacher MD. Arg-Gly-Asp: a versatile cell recognition signal. Cell. 1986;44:517-518.
2. Hynes R. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673-687.
3. Ma YQ, Yang J, Pesho MM, Vinogradova O, Qin J, Plow EF. Regulation of integrin αllbβ3 activation by distinct regions of its cytoplasmic tails.Biochemistry. 2006;45:6656-6662.
4. Wegener KL, Partridge AW, Han J, et al. Structural basis of integrin activation by talin. Cell. 2007;128:171-182.
5. Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol. 2007;25:619-647.
6. Kim M, Carman CV, Springer TA. Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins. Science. 2003;301:1720-1725.
7. Ginsberg MH, Partridge A, Shattil SJ. Integrin regulation. Curr Opin Cell Biol. 2005;17:1-8.
8. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8:1227-1234.
9. Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood. 2004;104:1606-1615.
10. Jackson SP. The growing complexity of platelet aggregation. Blood. 2007;109:5087-5095.
11. Phillips DR, Conley PB, Sinha U, Andre P. Therapeutic approaches in arterial thrombosis. J Thromb Haemost. 2005;3:1577-1589.
12. Chen Y-P, Djaffar I, Pidard D, et al. Ser-752-> Pro mutation in the cytoplasmic domain of integrin subunit and defective activation of platelet integrin αIIbβ3 (glycoprotein IIb-IIIa) in avariant of Glanzmann thrombasthenia. Proc Natl Acad Sci U S A. 1992;89:10169-10173.
13. Wang R, Shattil SJ, Ambruso DR, Newman PJ. Truncation of the cytoplasmic domain of β33in a variant form of Glanzmann thrombasthenia abrogates signaling through the integrin αllbβ33complex. J Clin Invest. 1997;100:2393-2403.
14. Zou Z, Chen H, Schmaier AA, Hynes RO, Kahn ML. Structure-function analysis reveals discrete β3 integrin inside-out and outside-in signaling pathways in platelets. Blood. 2007;109:3284-3290.
15. Petrich BG, Fogelstrand P, Partridge AW, et al. The antithrombotic potential of selective blockade of talin-dependent integrin αIIbβ3 (platelet GPIIb-IIIa) activation. J Clin Invest. 2007;117:2250-2259.
16. Leisner TM, Yuan W, DeNofrio JC, Liu J, Parise LV. Tickling the tails: cytoplasmic domain proteins that regulate integrin αlIbβ3 activation. Curr Opin Hematol. 2007;14:2552-2561.
17. Goksoy E, Ma YQ, Wang X, et al. Structural basis for the autoinhibition of talin in regulating integrin activation. Mol Cell. 2008;31:124-133.
18. Watanabe N, Bodin L, Pandey M, et al. Mechanisms and consequences of agonist-induced talin recruitment to platelet integrin αlIbβ3. J Cell Biol. 2008;181:1211-1222.
19. Arias-Salgado EG, Lizano S, Sarker S, Brugge JS, Ginsberg MH, Shattil SJ. Src kinase activation by a novel and direct interaction with the integrin β cytoplasmic domain. Proc Natl Acad Sci U S A. 2003;100:13298-13302.
20. Arias-Salgado EG, Lizano S, Shattil SJ, Ginsberg MH. Specification of the direction of adhesive signaling by the integrin β cytoplasmic domain. J Biol Chem. 2005;280:29699-29707.
21. Reddy KB, Smith DM, Plow EF. Analysis of Fyn function in hemostasis and αlIbβ3-integrin signaling. J Cell Sci. 2008;121:1641-1648.
22. Nieswandt B, Moser M, Pleines I, et al. Loss of talin1 in platelets abrogates integrin activation, platelet aggregation, and thrombus formation in vitro and in vivo. J Exp Med. 2007;204:3113-3118.
23. Petrich BG, Marchese P, Ruggeri ZM, et al. Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. J Exp Med. 2007;204:3103-3111.
24. Obergfell A, Eto K, Mocsai A, et al. Coordinate interactions of Csk, Src, and Syk kinases with αlIbβ3 initiate integrin signaling to the cytoskeleton. J Cell Biol. 2002;157:265-275.
25. Su X, Mi J, Yan J, et al. RGT, a synthetic peptide corresponding to the integrin β3 cytoplasmic C-terminal sequence, selectively inhibits outside-in signaling in human platelets by disrupting the interaction of integrin αIIbβ3 with Src kinase. Blood. 2008;112:592-602.
26. Law DA, DeGuzman FR, Heiser P, Ministri- Madrid K, Killeen N, Phillips DR. Integrin cytoplasmic tyrosine motif is required for outside-in αlIbβ3 signalling and platelet function. Nature. 1999;401:808-811.
27. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, et al. β3-integrin- deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest. 1999;103:229-238.
28. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003;2:15-28.
29. Lakso M, Pichel JG, Gorman JR, et al. Efficient in vivo manipulation of mouse genomic sequences at the zygote stage. Proc Natl Acad Sci U S A. 1996;93:5860-5865.
30. Konstantinides S, Schafer K, Thinnes T, Loskutoff DJ. Plasminogen activator inhibitor-1 and its co-factor vitronectin stabilize arterial thrombi after vascular injury in mice. Circulation. 2001;103:576-583.
31. Prevost N, Kato H, Bodin L, Shattil SJ. Platelet integrin adhesive functions and signaling. Methods Enzymol. 2007;426:103-115.
32. Arias-Salgado EG, Haj F, Dubois C, et al. PTP-1B is an essential positive regulator of platelet integrin signaling. J Cell Biol. 2005;170:837-845.
33. Lengweiler S, Smyth SS, Jirouskova M, et al. Preparation of monoclonal antibodies to murine platelet glycoprotein IIb/IIIa (αllβ3) and other proteins from hamster-mouse interspecies hybridomas. Biochem Biophys Res Commun. 1999;262:167-173.
34. Du XP, Saido TC, Tsubuki S, Indig FE, Williams MJ, Ginsberg MH. Calpain cleavage of the cytoplasmic domain of the integrin β3 subunit. J Biol Chem. 1995;270:26146-26151.
35. Pfaff M, Liu S, Erle DJ, Ginsberg MH. Integrin β cytoplasmic domains differentially bind to cytoskeletal proteins. J Biol Chem. 1998;273:6104-6109.
36. Calderwood DA, Zent R, Grant R, Rees DJG, Hynes RO, Ginsberg MH. The talin head domain binds to integrin β subunit cytoplasmic tails and regulates integrin activation. J Biol Chem. 1999;274:28071-28074.
37. Furie B, Furie BC. Thrombus formation in vivo. J Clin Invest. 2005;115:3355-3362.
38. Tsakiris DA, Scudder L, Hodivala-Dilke K, Hynes RO, Coller BS. Hemostasis in the mouse (Mus musculus): a review. Thromb Haemost. 1999;81:177-188.
39. Wonerow P, Pearce AC, Vaux DJ, Watson SP. A critical role for phospholipase Cγ2 in αIIbβ3-me-diated platelet spreading. J Biol Chem. 2003;278:37520-37529.
40. Jenkins AL, Nannizzi-Alaimo L, Silver D, et al. Tyrosine phosphorylation of the β3 cytoplasmic domain mediates integrin-cytoskeletal interactions. J Biol Chem. 1998;273:13878-13885.
41. Law DA, Nannizzi-Alaimo L, Cowan KJ, Prasad KS, Ramakrishnan V, Phillips DR. Signal transduction pathways for mouse platelet membrane adhesion receptors. Thromb Haemostas. 1999;82:345-352.
42. Xi X, Bodnar RJ, Li Z, Lam SC, Du X. Critical roles for the COOH-terminal NlTY and RGT sequences of the integrin β3 cytoplasmic domain in inside-out and outside-in signaling. J Cell Biol. 2003;162:329-339.
43. Tadokoro S, Shattil SJ, Eto K, et al. Talin binding to integrin β cytoplasmic tails: a final common step in integrin activation. Science. 2003;302:103-106.
44. Han J, Lim CJ, Watanabe N, et al. Reconstructing and deconstructing agonist-induced activation of integrin αIIbβ3. Curr Biol. 2006;16:1796-1806.
45. Montanez E, Ussar S, Schifferer M, et al. Kind-lin-2 controls bidirectional signaling of integrins. Genes Dev. 2008;22:1325-1330.
46. Moser M, Nieswandt B, Ussar S, Pozgajova M, Fassler R. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med. 2008;14:325-330.
47. Ma YQ, Qin J, Wu C, Plow EF. Kindlin-2 (Mig-2): a co-activator of β3 integrins. J Cell Biol. 2008;181:439-446.
48. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood. 1990;75:1383-1395.
49. Mahabeleshwar GH, Feng W, Phillips DR, Byzova TV. Integrin signaling is critical for pathological angiogenesis. J Exp Med. 2006;203:2495-2507.
50. Huveneers S, van den Bout I, Sonneveld P, Sancho A, Sonnenberg A, Danen EH. Integrin αVβ3 controls activity and oncogenic potential of primed c-Src. Cancer Res. 2007;67:2693-2700.
51. Zou W, Kitaura H, Reeve J, et al. Syk, c-Src, the αVβ3 integrin, and lTAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol. 2007;176:877-888.